Clinical Trials
1,486 trialsCRIRIN
University Hospital, Strasbourg, France
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Actelion
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
Bristol-Myers Squibb
SITISVEAL
Grupo Español Multidisciplinar de Melanoma
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
Match Mel
Melanoma Institute Australia
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
KEYMAKER-U02
Merck Sharp & Dohme LLC
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
ENZYMELA
Assistance Publique - Hôpitaux de Paris
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
PanRAF
Royal Marsden NHS Foundation Trust
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
FHAMe
University of Toronto
TUPRO
University of Zurich
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
NAVIGATE
Bayer
Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma
Soul Medicine Institute
COMBI-AD
Novartis
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
MELANFα
Institut Claudius Regaud
TraveraRTGx
Travera Inc
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
University of California, San Francisco
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
STARS
University of Utah
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
Bio-Thera Solutions
Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma
Centre Hospitalier Universitaire de Nice
AMMAM
Centre Hospitalier Universitaire de Nice
DOPACER
Institut Cancerologie de l'Ouest
TICIMEL
Institut Claudius Regaud
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
LN-144
Iovance Biotherapeutics, Inc.
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
The Christie NHS Foundation Trust
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
LEGIT_MC_EVCDA
AI Labs Group S.L
MK-4700-001
Merck Sharp & Dohme LLC
Lipo-MERIT
BioNTech SE
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
IMMUMELA
Assistance Publique - Hôpitaux de Paris